Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

2.86USD
3:44pm BST
Change (% chg)

$-0.01 (-0.52%)
Prev Close
$2.87
Open
$2.88
Day's High
$2.88
Day's Low
$2.80
Volume
75,583
Avg. Vol
471,190
52-wk High
$4.59
52-wk Low
$2.36

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $950.48
Shares Outstanding(Mil.): 270.79
Dividend: --
Yield (%): --

Financials

  AMRN.OQ Industry Sector
P/E (TTM): -- 85.69 32.76
EPS (TTM): -0.31 -- --
ROI: -101.25 1.78 14.61
ROE: -- 3.28 16.33

BRIEF-Amarin Corporation Reports Q1 GAAP Loss Per Share $0.08

* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

02 May 2018

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

04 Apr 2018

BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE

* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS

04 Apr 2018

BRIEF-Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa

* AMARIN CORPORATION PLC - ‍MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA​

21 Mar 2018

BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share

* AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

27 Feb 2018

Earnings vs. Estimates